Evidence map›Paper›PMID 42735941›Full record

ArticleCMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne2026

Impact of drug decriminalization and recriminalization on drug-related crime and health outcomes in British Columbia: a population-level time-series analysis.

Adrienne Gaudreault, Maya Gibb, Robert Talarico, Matthew Herder, Benedikt Fischer, Andrew D Pinto, Daniel T Myran

Abstract read
In one paragraph

Article in CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. What decriminalization in British Columbia could and could not achieve.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Adrienne GaudreaultFaculty of Medicine (Gaudreault, Herder), Dalhousie University, Halifax, NS; Faculty of Health Sciences, School of Medicine (Gibb), Queen's University, Kingston, Ont.; ICES uOttawa (Talarico), Ottawa Hospital Research Institute, Ottawa, Ont.; Schulich School of Law (Herder), Dalhousie University, Halifax, NS; Faculty of Health Sciences (Fischer), Simon Fraser University, Burnaby, BC; Waypoint Research Institute (Fischer), Waypoint Centre for Mental Health Care, Penetanguishene, Ont.; Research and Graduate Studies (Fischer), University of the Fraser Valley, Abbotsford, BC; Department of Psychiatry (Fischer), University of Toronto, Toronto, Ont.; Department of Psychiatry (Fischer), Federal University of São Paulo, São Paulo, Brazil; School of Population Health (Fischer), University of Auckland, Auckland, New Zealand; Dalla Lana School of Public Health (Pinto), University of Toronto; Department of Family and Community Medicine (Pinto), St. Michael's Hospital; Upstream Lab, MAP, (Pinto) Li Ka Shing Knowledge Institute, Unity Health Toronto; Department of Family and Community Medicine (Pinto), Faculty of Medicine; Department of Family and Community Medicine (Myran), North York General Hospital, Toronto, Ont.; Department of Family Medicine (Myran), University of Ottawa; Bruyère Health Research Institute (Myran), Ottawa, Ont.; Department of Family Medicine (Myran), University of Toronto, Toronto, Ont.
Maya GibbFaculty of Medicine (Gaudreault, Herder), Dalhousie University, Halifax, NS; Faculty of Health Sciences, School of Medicine (Gibb), Queen's University, Kingston, Ont.; ICES uOttawa (Talarico), Ottawa Hospital Research Institute, Ottawa, Ont.; Schulich School of Law (Herder), Dalhousie University, Halifax, NS; Faculty of Health Sciences (Fischer), Simon Fraser University, Burnaby, BC; Waypoint Research Institute (Fischer), Waypoint Centre for Mental Health Care, Penetanguishene, Ont.; Research and Graduate Studies (Fischer), University of the Fraser Valley, Abbotsford, BC; Department of Psychiatry (Fischer), University of Toronto, Toronto, Ont.; Department of Psychiatry (Fischer), Federal University of São Paulo, São Paulo, Brazil; School of Population Health (Fischer), University of Auckland, Auckland, New Zealand; Dalla Lana School of Public Health (Pinto), University of Toronto; Department of Family and Community Medicine (Pinto), St. Michael's Hospital; Upstream Lab, MAP, (Pinto) Li Ka Shing Knowledge Institute, Unity Health Toronto; Department of Family and Community Medicine (Pinto), Faculty of Medicine; Department of Family and Community Medicine (Myran), North York General Hospital, Toronto, Ont.; Department of Family Medicine (Myran), University of Ottawa; Bruyère Health Research Institute (Myran), Ottawa, Ont.; Department of Family Medicine (Myran), University of Toronto, Toronto, Ont.
Robert TalaricoFaculty of Medicine (Gaudreault, Herder), Dalhousie University, Halifax, NS; Faculty of Health Sciences, School of Medicine (Gibb), Queen's University, Kingston, Ont.; ICES uOttawa (Talarico), Ottawa Hospital Research Institute, Ottawa, Ont.; Schulich School of Law (Herder), Dalhousie University, Halifax, NS; Faculty of Health Sciences (Fischer), Simon Fraser University, Burnaby, BC; Waypoint Research Institute (Fischer), Waypoint Centre for Mental Health Care, Penetanguishene, Ont.; Research and Graduate Studies (Fischer), University of the Fraser Valley, Abbotsford, BC; Department of Psychiatry (Fischer), University of Toronto, Toronto, Ont.; Department of Psychiatry (Fischer), Federal University of São Paulo, São Paulo, Brazil; School of Population Health (Fischer), University of Auckland, Auckland, New Zealand; Dalla Lana School of Public Health (Pinto), University of Toronto; Department of Family and Community Medicine (Pinto), St. Michael's Hospital; Upstream Lab, MAP, (Pinto) Li Ka Shing Knowledge Institute, Unity Health Toronto; Department of Family and Community Medicine (Pinto), Faculty of Medicine; Department of Family and Community Medicine (Myran), North York General Hospital, Toronto, Ont.; Department of Family Medicine (Myran), University of Ottawa; Bruyère Health Research Institute (Myran), Ottawa, Ont.; Department of Family Medicine (Myran), University of Toronto, Toronto, Ont.
Matthew HerderFaculty of Medicine (Gaudreault, Herder), Dalhousie University, Halifax, NS; Faculty of Health Sciences, School of Medicine (Gibb), Queen's University, Kingston, Ont.; ICES uOttawa (Talarico), Ottawa Hospital Research Institute, Ottawa, Ont.; Schulich School of Law (Herder), Dalhousie University, Halifax, NS; Faculty of Health Sciences (Fischer), Simon Fraser University, Burnaby, BC; Waypoint Research Institute (Fischer), Waypoint Centre for Mental Health Care, Penetanguishene, Ont.; Research and Graduate Studies (Fischer), University of the Fraser Valley, Abbotsford, BC; Department of Psychiatry (Fischer), University of Toronto, Toronto, Ont.; Department of Psychiatry (Fischer), Federal University of São Paulo, São Paulo, Brazil; School of Population Health (Fischer), University of Auckland, Auckland, New Zealand; Dalla Lana School of Public Health (Pinto), University of Toronto; Department of Family and Community Medicine (Pinto), St. Michael's Hospital; Upstream Lab, MAP, (Pinto) Li Ka Shing Knowledge Institute, Unity Health Toronto; Department of Family and Community Medicine (Pinto), Faculty of Medicine; Department of Family and Community Medicine (Myran), North York General Hospital, Toronto, Ont.; Department of Family Medicine (Myran), University of Ottawa; Bruyère Health Research Institute (Myran), Ottawa, Ont.; Department of Family Medicine (Myran), University of Toronto, Toronto, Ont.
Benedikt FischerFaculty of Medicine (Gaudreault, Herder), Dalhousie University, Halifax, NS; Faculty of Health Sciences, School of Medicine (Gibb), Queen's University, Kingston, Ont.; ICES uOttawa (Talarico), Ottawa Hospital Research Institute, Ottawa, Ont.; Schulich School of Law (Herder), Dalhousie University, Halifax, NS; Faculty of Health Sciences (Fischer), Simon Fraser University, Burnaby, BC; Waypoint Research Institute (Fischer), Waypoint Centre for Mental Health Care, Penetanguishene, Ont.; Research and Graduate Studies (Fischer), University of the Fraser Valley, Abbotsford, BC; Department of Psychiatry (Fischer), University of Toronto, Toronto, Ont.; Department of Psychiatry (Fischer), Federal University of São Paulo, São Paulo, Brazil; School of Population Health (Fischer), University of Auckland, Auckland, New Zealand; Dalla Lana School of Public Health (Pinto), University of Toronto; Department of Family and Community Medicine (Pinto), St. Michael's Hospital; Upstream Lab, MAP, (Pinto) Li Ka Shing Knowledge Institute, Unity Health Toronto; Department of Family and Community Medicine (Pinto), Faculty of Medicine; Department of Family and Community Medicine (Myran), North York General Hospital, Toronto, Ont.; Department of Family Medicine (Myran), University of Ottawa; Bruyère Health Research Institute (Myran), Ottawa, Ont.; Department of Family Medicine (Myran), University of Toronto, Toronto, Ont.
Andrew D PintoFaculty of Medicine (Gaudreault, Herder), Dalhousie University, Halifax, NS; Faculty of Health Sciences, School of Medicine (Gibb), Queen's University, Kingston, Ont.; ICES uOttawa (Talarico), Ottawa Hospital Research Institute, Ottawa, Ont.; Schulich School of Law (Herder), Dalhousie University, Halifax, NS; Faculty of Health Sciences (Fischer), Simon Fraser University, Burnaby, BC; Waypoint Research Institute (Fischer), Waypoint Centre for Mental Health Care, Penetanguishene, Ont.; Research and Graduate Studies (Fischer), University of the Fraser Valley, Abbotsford, BC; Department of Psychiatry (Fischer), University of Toronto, Toronto, Ont.; Department of Psychiatry (Fischer), Federal University of São Paulo, São Paulo, Brazil; School of Population Health (Fischer), University of Auckland, Auckland, New Zealand; Dalla Lana School of Public Health (Pinto), University of Toronto; Department of Family and Community Medicine (Pinto), St. Michael's Hospital; Upstream Lab, MAP, (Pinto) Li Ka Shing Knowledge Institute, Unity Health Toronto; Department of Family and Community Medicine (Pinto), Faculty of Medicine; Department of Family and Community Medicine (Myran), North York General Hospital, Toronto, Ont.; Department of Family Medicine (Myran), University of Ottawa; Bruyère Health Research Institute (Myran), Ottawa, Ont.; Department of Family Medicine (Myran), University of Toronto, Toronto, Ont.
Daniel T MyranFaculty of Medicine (Gaudreault, Herder), Dalhousie University, Halifax, NS; Faculty of Health Sciences, School of Medicine (Gibb), Queen's University, Kingston, Ont.; ICES uOttawa (Talarico), Ottawa Hospital Research Institute, Ottawa, Ont.; Schulich School of Law (Herder), Dalhousie University, Halifax, NS; Faculty of Health Sciences (Fischer), Simon Fraser University, Burnaby, BC; Waypoint Research Institute (Fischer), Waypoint Centre for Mental Health Care, Penetanguishene, Ont.; Research and Graduate Studies (Fischer), University of the Fraser Valley, Abbotsford, BC; Department of Psychiatry (Fischer), University of Toronto, Toronto, Ont.; Department of Psychiatry (Fischer), Federal University of São Paulo, São Paulo, Brazil; School of Population Health (Fischer), University of Auckland, Auckland, New Zealand; Dalla Lana School of Public Health (Pinto), University of Toronto; Department of Family and Community Medicine (Pinto), St. Michael's Hospital; Upstream Lab, MAP, (Pinto) Li Ka Shing Knowledge Institute, Unity Health Toronto; Department of Family and Community Medicine (Pinto), Faculty of Medicine; Department of Family and Community Medicine (Myran), North York General Hospital, Toronto, Ont.; Department of Family Medicine (Myran), University of Ottawa; Bruyère Health Research Institute (Myran), Ottawa, Ont.; Department of Family Medicine (Myran), University of Toronto, Toronto, Ont. daniel.myran@nygh.on.ca.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDrug decriminalization has been proposed to reduce health and social harms related to illicit substance use. We sought to evaluate changes in outcomes following drug decriminalization and partial recriminalization in British Columbia.

methodsWe obtained data from August 2020 to March 2025 on police-recorded drug incidents nationally from Statistics Canada, opioid- and stimulant-related hospitalizations nationally (excluding Quebec) from the Canadian Institute for Health Information, and drug toxicity deaths in BC, Alberta, and Ontario from provincial, publicly available data sources. We used a controlled interrupted time-series design to compare changes in monthly rates of drug-related hospitalizations and deaths and drug possession incidents between BC and the rest of Canada after decriminalization (February 2023) and subsequent recriminalization (May 2024).

resultsOver the 5-year period, 97 630 drug possession incidents, 161 278 opioid-and 113 747 stimulant-related hospitalizations, and 29 730 drug toxicity deaths occurred in the study regions. In BC, drug possession incidents decreased after decriminalization (incidence rate ratio [IRR] 0.61, 95% confidence interval [CI] 0.42 to 0.86) and increased again after recriminalization (IRR 1.68, 95% CI 1.13 to 2.51), while no significant changes were observed in the rest of Canada. After decriminalization, BC did not differ significantly from other provinces and territories for changes in opioid-related hospitalizations (ratio of rate ratios [RRR] 0.87, 95% CI 0.54 to 1.42), stimulant-related hospitalizations (RRR 0.77, 95% CI 0.50 to 1.28), or deaths from drug toxicity (RRR v. Alberta 0.83, 95% CI 0.64 to 1.06; RRR v. Ontario 1.07, 95% CI 0.64 to 1.78). After recriminalization in BC, changes remained similar to other provinces and territories for opioid-related hospitalizations (RRR 1.03, 95% CI 0.56 to 1.90) and stimulant-related hospitalizations (RRR 1.02, 95% CI 0.59 to 1.76), and similar to Alberta for deaths from drug toxicity (RRR 1.14, 95% CI 0.79 to 1.66).

interpretationDrug decriminalization and recriminalization in BC were associated with substantial changes in police-reported drug possession incidents but no corresponding changes in drug toxicity deaths or hospitalizations when compared to other regions in Canada. The findings suggest decriminalization is effective at reducing drug possession incidents but is insufficient in isolation to affect health outcomes.

Indexed as

CrimeDrug and Narcotic ControlHospitalizationIllicit DrugsSubstance-Related DisordersAnalgesics, OpioidBritish ColumbiaHumansInterrupted Time Series AnalysisAnalgesics, OpioidIllicit Drugs

Identifiers

PMID42735941
PMCPMC13585393

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.